AbbVie (NYSE:ABBV) Q4 2025 Earnings call February 04, 2026 09:00 AM ET Company ParticipantsAsad Haider - Managing Director in Equity Research of Healthcare and Biotech CompaniesDavid Risinger - Senior Managing DirectorJeff Stewart - EVP of Chief Commercial OfficerLiz Shea - SVP of Investor RelationsLuisa Hector - Head of Global Pharma Equity ResearchMark Hoffman - Senior Equity Research Associate of BioPharmaMichael Yee - Global Head of Biotechnology Equity Research and Managing DirectorMohit Bansal - Manag ...

AbbVie (NYSE:ABBV) Q4 2025 Earnings call February 04, 2026 09:00 AM ET Company ParticipantsAsad Haider - Managing Director in Equity Research of Healthcare and Biotech CompaniesDavid Risinger - Senior Managing DirectorJeff Stewart - EVP of Chief Commercial OfficerLiz Shea - SVP of Investor RelationsLuisa Hector - Head of Global Pharma Equity ResearchMark Moffman - Senior Equity Research Associate of BioPharmaMichael Yee - Global Head of Biotechnology Equity Research and Managing DirectorMohit Bansal - Manag ...

AbbVie (NYSE:ABBV) Q4 2025 Earnings call February 04, 2026 09:00 AM ET Speaker2Good morning, and thank you for standing by. Welcome to the AbbVie fourth quarter 2025 earnings conference call. All participants will be able to listen only until the question-and-answer portion of this call. You may ask a question by pressing star or one on your phone. Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would now like to introduce Ms. Liz Shea, Senior Vice Preside ...

由于为提振低迷医美业务所做的一系列举措开始见效，艾伯维(ABBV.US)周三公布了超预期的第四季度 业绩，同时上调了2026年盈利指引。 2025年，艾伯维免疫学业务全球净营收达304亿美元，同比增长14%。四季度，Rinvoq和Skyrizi销售额 分别为24亿美元和50亿美元，基本符合市场预期。 其中，该公司医美业务显现复苏迹象：尽管Juvederm产品销售额未达预期，但Botox实现销售额7.17亿 美元，自2024年第三季度以来首次实现增长，超过分析师6.839亿美元的平均预期。神经科学产品线方 面，精神分裂症治疗药物Vraylar销售额突破10亿美元，高于市场9.853亿美元的预期。 展望未来，该公司预计2026年经调整后每股收益将在14.37至14.57美元之间，而分析师的平均预期为 14.22美元。 财报公布后，艾伯维盘前一度上涨1.75%，但随后转跌近3%。截至周二收盘，这家总部位于伊利诺伊州 北芝加哥市的制药企业今年以来股价累计下跌1.2%。 对艾伯维而言，2025年是其关节炎药物Humira(曾为全球最畅销药物)失去市场独占权后的第二个完整年 度，四季度，Humira的全球销售额下降25. ...

Key Takeaways AbbVie reports Q4 and full-year 2025 earnings Feb. 4, with sales expected above $16.3B and EPS near $2.66.ABBV's newer immunology drugs Skyrizi and Rinvoq are expected to fuel growth as Humira sales keep declining.AbbVie stock trades below industry P/E, driven by a growing pipeline and diversification across franchises.AbbVie (ABBV) is set to report fourth-quarter and full-year 2025 earnings on Feb. 4, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings i ...

Group 1: Eli Lilly - Eli Lilly became the first healthcare company to join the trillion-dollar club, driven by its leadership in the weight-loss market and the success of its drug tirzepatide, which became the world's best-selling compound last year [3][6] - The company is expected to receive approval for Orforglipron, an oral medication for diabetes and weight loss, which will further enhance its market position [4] - Eli Lilly's innovative culture and strong financial results make it an excellent buy-and-hold option, with potential for significant revenue growth from its weight-loss portfolio [7] Group 2: AbbVie - AbbVie has a diverse product portfolio with key growth drivers in its immunology segment, particularly with drugs like Skyrizi and Rinvoq, and has successfully managed the loss of patent exclusivity for Humira [8][10] - The company is recognized as a dividend growth powerhouse, being part of the Dividend Kings group, which has raised payouts for at least 50 consecutive years, making it a strong long-term investment [11] - AbbVie is actively working on a vast pipeline to address upcoming patent expirations, ensuring a steady flow of new products [10] Group 3: Intuitive Surgical - Intuitive Surgical is a leader in robotic-assisted surgery systems, particularly known for its da Vinci system, which has a competitive advantage due to high switching costs for hospitals [12][13] - The company continues to expand its installed base and benefits from increasing procedure volumes, which are crucial for revenue growth [15] - Long-term growth is supported by demographic trends such as the aging population, positioning Intuitive Surgical for competitive returns [16]

AbbVie Conference Call Summary Company Overview - **Company**: AbbVie - **Key Executives Present**: Scott Reents (CFO), Jeff Stewart (Chief Commercial Officer), Roopal Thakkar (Chief Medical Officer) Key Industry Insights 1. Financial Performance and Strategy - AbbVie aims to deliver strong financial results and advance its pipeline as it approaches 2026, continuing the strategy established in previous years [3][4] - The company anticipates a peak sales guidance for 2025, projecting an overall sales growth of approximately $7 billion from 2023 to 2025, despite a $10 billion erosion from Humira and $2 billion from the IRA [4] - The growth platform, excluding Humira, is expected to grow by roughly $15 billion, with the neuroscience portfolio contributing an additional $3 billion [4] - Overall business growth is projected at around 8% for the top line, with the growth platform achieving approximately 19% growth [4] 2. Long-term Growth Projections - AbbVie has set a long-term guidance for high single-digit compound annual growth rate (CAGR) through the decade, with expectations to maintain this growth into the 2030s [7] - The company plans to invest approximately $9 billion in R&D for 2025, representing nearly 15% of sales, with expectations for EPS to expand faster than sales due to improved operating margins [7][8] 3. Pipeline Development - AbbVie is focused on advancing its pipeline, with anticipated approvals for Vyalev and Tavapadon, and indication expansions for Rinvoq, Ubrelvy, and Qulipta [5] - Pivotal data for Lutikizumab and Itentamig is expected in the near future, with a strong emphasis on developing growth drivers for the next decade [5] 4. Market Dynamics and Competitive Landscape - The company acknowledges that while the strength of its franchises, particularly in Immunology and Neuroscience, is recognized, there is still a need to emphasize the durability and potential of these segments [9] - Neuroscience is highlighted as the fastest-growing franchise, with expectations to become the largest player in the industry soon [9] - The oncology pipeline is also noted as underappreciated, with several promising assets in development [9] 5. Pricing and Market Access - AbbVie anticipates low single-digit pricing headwinds for its immunology brands, with a competitive landscape that remains stable despite market pressures [34][35] - The company is adapting to changes in the pharmacy benefit manager (PBM) landscape, emphasizing its ability to operate effectively in various pricing models [64][65] 6. Aesthetics and Consumer Engagement - The aesthetics business, particularly in the HA filler market, has faced challenges but remains a key part of AbbVie's strategy, with plans for significant consumer investments to revitalize the market [52][53] - The introduction of Trinibot E, a short-acting toxin, is expected to address consumer concerns about appearance and cost, enhancing market penetration [55] 7. Future Opportunities - AbbVie is exploring opportunities in the obesity market, focusing on the tolerability and durability of weight loss therapies, with a strategic interest in expanding its portfolio in this area [61][62] - The company is also committed to enhancing its pipeline through strategic acquisitions and partnerships, having completed nearly 40 transactions since early 2024, deploying approximately $8 billion [58][60] Conclusion - AbbVie is positioned for continued growth through strategic execution, robust pipeline development, and a focus on market dynamics. The company is committed to maintaining its leadership in key therapeutic areas while adapting to evolving market conditions and consumer needs.

Core Insights - Investors are showing a bullish stance on AbbVie (NYSE:ABBV), indicating potential upcoming developments that may influence the stock price [1][2] - The options trading activity reveals a split sentiment among large investors, with 43% bullish and 43% bearish positions [3] Options Trading Activity - Benzinga's options scanner identified 16 uncommon options trades for AbbVie, with a total of $1,449,383 in call options and $97,520 in put options [2][3] - Major market movers are focusing on a price range between $120.0 and $250.0 for AbbVie over the last three months [4] - The volume and open interest data for AbbVie's options indicate significant liquidity and interest, particularly within the strike price range of $120.0 to $250.0 [5] Options Snapshot - Notable options trades include: - A bearish call sweep for a strike price of $220.00 with a total trade price of $293.4K [9] - A bullish call sweep for a strike price of $230.00 with a total trade price of $226.5K [9] - Additional bearish call sweeps for the same strike price of $220.00 with total trade prices of $190.9K and $183.3K [9] Company Overview - AbbVie is a pharmaceutical company with strong exposure in immunology and oncology, having expanded its portfolio through acquisitions, including Allergan in 2020 and recent acquisitions of Cerevel and ImmunoGen [10] - Current market consensus from analysts suggests a target price of $267.0 for AbbVie, with ratings from Morgan Stanley and HSBC indicating an Overweight and Buy rating, respectively [12][13] Current Market Performance - AbbVie’s stock price is currently at $225.83, reflecting a 0.97% increase with a trading volume of 2,394,007 [15] - The stock's current RSI values suggest a neutral position between overbought and oversold [15]

Core Insights - Financial giants are showing a bearish sentiment towards AbbVie, with 33% of traders indicating bearish tendencies compared to 11% bullish [1] - Significant investors are targeting a price range for AbbVie between $100.0 and $260.0 over the past three months [2] - AbbVie has a diverse portfolio in immunology and oncology, bolstered by recent acquisitions [8] Trading Activity - Recent options activity for AbbVie includes 9 unusual trades, with 4 puts valued at $326,123 and 5 calls valued at $230,186 [1] - The largest observed options trades include neutral sentiment for puts and bullish sentiment for certain calls, with notable strike prices [7] Analyst Ratings - Analysts have varying target prices for AbbVie, with an average target of $251.0 and individual targets ranging from $220 to $289 [10][11] - JP Morgan maintains an Overweight rating with a target price of $260, while UBS and Citigroup hold Neutral ratings with targets of $220 and $235 respectively [11] Current Performance - AbbVie’s stock price is currently at $229.06, reflecting a decrease of 1.65% with a trading volume of 1,945,474 [13] - The next earnings report for AbbVie is scheduled in 71 days, and current RSI values indicate a neutral position [13]

Biotech M&A Activity - Merck announced the acquisition of Cidara Therapeutics for approximately $9.2 billion, primarily for its antiviral drug aimed at preventing flu infections in high-risk patients, currently in late-stage clinical trials [1] - This acquisition follows Merck's earlier $10 billion deal to acquire Verona Pharma for respiratory drugs, indicating a trend of significant investments in biotech [1] - The dollar volume of M&A in the biotech sector reached $129 billion through October 31, 2025, a 43% increase compared to all of 2024, despite a 26% decrease in the number of deals, highlighting a shift towards larger, market-ready assets [3] Recursion's Challenges - Recursion has not successfully brought any drugs to market since its founding, with its shares dropping 86% since its IPO in April 2021, resulting in a current market cap of $2.2 billion [4] - The company reported a revenue decline of one-third to $44 million from $65 million over the last 12 months, while losses surged nearly 90% to $716 million [4] - Incoming CEO Najat Khan aims to tackle the challenges of AI in drug development, acknowledging the high failure rate in the industry [5] Infant Formula Outbreak - A botulism outbreak linked to ByHeart's organic infant formula affected 23 babies across 13 states, leading to multiple hospitalizations and five lawsuits from parents [6] - ByHeart had previously shut down its Pennsylvania manufacturing plant due to safety violations and announced a nationwide recall of its infant formula [7] Profluent's AI Innovations - Profluent, a startup focused on using AI for protein design, raised $106 million in new venture funding, bringing its total investment to $150 million and approaching a valuation of $1 billion [12] - The company aims to revolutionize drug development and agriculture by making biology programmable, which could lead to significant breakthroughs in therapeutics and diagnostics [11]